An Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, Pharmacokinetics, and Efficacy of WVE-N531 in Patients With Duchenne Muscular Dystrophy Who Participated in Another Study of WVE-N531
Latest Information Update: 15 Oct 2025
At a glance
- Drugs WVE-N531 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors WaVe life Sciences
Most Recent Events
- 15 Oct 2025 New trial record